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HIV/AIDS poses a unique challenge to businesses, 
particularly those operating in Southern Africa. The region is 
home to one third of the worldwide HIV positive population 
(as measured by those aged 15 to 49) yet as a whole 
contributes a diminutive proportion of the total worldwide 
population by the same measure (UNAIDS, 2016; World 
Bank, 2016). 
Relative to its size, the epidemic has introduced disparately 
large economic strain due to the fact that the highest HIV 
prevalence rates coincide with the most productive years of 
people’s lives, with prevalence rates peaking around the 30 to 
34-year-old stratum (Shisana, et al., 2012). Loss of business 
productivity as a result of HIV related illness through a 
combination of absenteeism and so called ‘presenteeism’1 as 
well as death due to AIDS and the resultant increase in 
employee turnover, has motivated companies to implement 
workplace HIV education, prevention and treatment 
programmes over and above governments’ efforts to curb the 
effect of the disease on business operations and the associated 
economic costs (Granich et al., 2012; Meyer-Rath et al., 2012, 
2015). 
As Rosen et. al. argue, HIV/AIDS is impacting two of the 
fundamental pillars behind the rationale driving investment in 
developing countries – that is; cheap labour and rapid market 
growth (Rosen, et al., 2003). 
 
Fortunately, since the advent of effective antiretroviral therapy 
(ART), coupled with the massive drop in treatment costs over 
the years, HIV is no longer a death sentence, nor does the 
virus, under suppression, cause noticeable direct long-term 
disability if managed effectively (Deeks, Lewin, & Havlir, 
2013; Menzies et al., 2011). This has introduced the 
opportunity for businesses to intervene with comprehensive 
treatment and care programmmes for their HIV positive 
employees in order to fight back at an epidemic that would 
otherwise be crippling.  
 
At the time of any given employee contracting HIV, and given 
a no-intervention-scenario, a company can immediately 
conceptualize a contingent liability in the form of loss in 
productivity, increase in medical costs, increase in absentee 
days and death benefit payments should the employee die 
from AIDS. In order to mitigate these risks, companies ought 
to provide access to ART, following which, the contingent 
liability of AIDS related events should fall dramatically when 
compared to a no-treatment-scenario (Freedberg et al., 2001; 
INSIGHT START Study Group, 2015). HIV has become an 
unavoidable concern for businesses operating in high HIV 
prevalence countries, and so, the provision of ART must be 
assessed as a prudent investment decision rather than merely a 
stream of costs (Rosen, et al., 2004), and as with any 
investment should be acted on based on its merits. This paper 
aims to quantify the benefits of the provision of ART to HIV 
positive employees, as well as employers, through the analysis 
of the in-house HIV management programme implemented at 
Anglo American Coal South Africa (AACSA). 
 
The data used to conduct this analysis come from the 
proprietary health information system (‘theHealthSource’) 
developed at AACSA in an effort to better manage health 
                                                        
1 Presenteeism refers to a reduction in on-the-job productivity 
usually attributed to illness (Hemp, 2004).  
outcomes, treatment efficacies, as well as allow for the 
provision of information necessary for health programme 
evaluations. AACSA has  provided access to its 
comprehensive data base of its workforce’s health, 
anonymously linking HIV treatment statuses, and HR records, 
dating back to 2009. The exclusivity of these type of data, in 
any such scenario, is what makes this analysis unique among 
most. The Anglo American group of companies is at the 
forefront of company-level HIV treatment and monitoring, 
thus providing few scenarios in which the base of this analysis 
could be improved upon.  
 
The monitoring and evaluation of these types of programmes 
plays an instrumental role in the advocacy of in-house HIV 
treatment strategies, and perhaps treatment of chronic illness 
as a whole.   
What follows in this paper is an analysis of the company-level 
ART programme with the aim of gaining an understanding 
into a number of key factors through which ART and 




The data used in this analysis were taken from a system that 
has generated unique random identifiers per employee, with 
no way to trace these identifiers back to any individual within 
the company. For the majority of the data, the patients had 
explicitly agreed to make available their disidentified data for 
monitoring and evaluation purposes. The individual level data 
within the company have been kept confidential at every level 
beyond the direct and specific use of it for medical treatment 
and care.  Ethical approval for this study was granted by the 








Worldwide, South Africa, with an HIV positive population of 
7,1 million people, is the country most heavily burdened by 
the epidemic (UNAIDS, 2016). As of 2016 18,9% of the 
overall working-age population is living with the disease. In 
many sub populations, however, the HIV prevalence rate 
reaches much higher levels (Shisana et al., 2014). The high 
prevalence rate, coupled with the fact that, historically, the 
background incidence of infectious diseases is generally high 
in developing countries such as South Africa, creates for an 
incubator in which opportunistic infections are able to thrive 
(Corbett et al., 2003).  
 
Beyond the cost of HIV and AIDS to individuals, companies 
share in the burden of the disease in the form of increased 
costs attributable to heavy productivity losses, increased staff 
turnover due to ill health retirements and AIDS related 
mortality, as well as increased general healthcare programme 
costs. For this reason, companies, over and above the public 
sector, share in the incentive to provide antiretroviral therapy 
in order to combat the effects of the epidemic. 
 
Antiretroviral therapy has been shown to not only drastically 
prolong the lives of HIV positive individuals but also 
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significantly reduce the risk of transmission of the virus from 
those on treatment with suppressed viral loads to HIV 
negative people (Deeks, Lewin, & Havlir, 2013; Menzies et 
al., 2011; Attia, Egger, Müller, Zwahlen, & Low, 2009).  
 
The hidden threat of HIV for businesses lies in the somewhat 
unique pathogenesis of the virus in which HIV positive people 
can live asymptomatic and otherwise completely normal and 
healthy lives for 5 to 10 years following initial infection 
(Rosen, et al., 2004)(Kenya). The virus, thus, has the ability to 
penetrate populations with few, if any, short term 
consequences yet cause deep structural damage to the long-
term prospects of any business or economy in which it 
infiltrates  (Poku, 2004). For this reason it can be hard to 
convince management of the necessities of tackling a problem 
which they cannot see, or at the very least, and for all 
purposes, is considered to be a distant problem. As Rosen et. 
al. argue, the cost of HIV/AIDS for employers must be based 
on prevalence and not incidence – that is, the discounted cost 
of an HIV infection must be measured at the time of 
contraction of the virus and not at the time symptoms appear if 
organisations are to justify the cost of prevention and 
treatment  (Rosen, Simon, Thea, & Vincent, 2000).  
 
HIV has vastly differing prevalence rates and distributions 
across regions, genders, age, ethnic groups, sexual orientations 
as well various other sub-populations such as migrant labour 
(Shisana et al., 2014) (Brummer, 2002).By virtue of this, the 
epidemic also has vastly differing implications for businesses 
dependent on these sub-populations (Barnett & Whiteside, 
1999). Historically, migrant labour has been a particularly 
significant risk factor in the susceptibility to HIV infection 
(Lurie, 2006), driven, in part, by the fact that these workers 
live away from their families, often in single sex hostels, with 
affordable access to alcohol and sex workers – all of which 
contribute to risky sexual behaviours (Crush, Williams, 





If HIV is allowed to progress to full-blown AIDS, there is a 
dramatic increase in the incidence, length and severity of 
opportunistic infections, chief of which and overall the 
deadliest for those suffering with AIDS, is tuberculosis 
(Barnett & Whiteside, 2000)(Southern Africa) – a disease 
which has accelerated off the back of the HIV epidemic. 
Among most of the Southern African countries the proportion 
of people with incident TB infections who are HIV positive 
sits at more than 60% (World Health Organisation, 2016), 
with HIV coinfection of incident TB cases in South Africa 
sitting at above 70% (SANAC, 2011). This is of particular 
concern for mining companies whose employees, beyond just 
being at a higher risk for HIV infection through the exposure 
to a number of risk factors (Lurie, 2006), are, under some 
circumstances, exposed to inhaled particulates such as 
crystalline silica dust which can create a predisposition to TB 
infection through the development of pneumoconiosis 
(Goldstein & Webster, 1972; Kim et al., 2009). The triad of 
HIV, TB and pneumoconiosis creates a particularly 
devastating burden of disease in the mining industry. 
 
In Sub-Saharan African countries, where HIV-TB coinfection 
rates are abnormally high, the provision of ART has been 
shown to be a cost-effective means of TB management 
(Williams, et al., 2010), and, indeed, a highly effective means 
of management of all opportunistic infections. Anecdotal 
evidence shared by Anglo American Coal South Africa 
suggests that their response in rolling out HIV treatment has 
drastically reduced the annual incidence of opportunistic TB 
infections, although the causality of this relationship is yet to 
be established, and generally beyond the scope of our analysis, 
in which we look primarily at the relationship between HIV 
treatment and company reported sick days, as well as clinical 
visits per employee. 
 
The primary mechanism of clinical action of ART is in the 
reduction of HIV viral loads and the resultant preservation of 
healthy CD4 counts in HIV positive individuals. Generally, if 
treatment is working, those on ART will have much higher 
CD4 counts as well as lower viral loads than those not on 
ART when conditioned on the length of time from HIV 
infection (Battegay, Nüesch, Hirschel, & Kaufmann, 2006), 
and when used effectively for those presenting with varying 
degrees of immunosuppression, has the potential to allow 
recovery of CD4 counts in treated HIV positive people to the 
point where CD4 counts are normalized and comparable to 
those observed in HIV negative groups (Mocroft et al., 2007). 
Those not suffering the effects of immunosupression under 
similar circumstances to those with varying degrees of HIV 
induced immunosuppression are far less likely to contract 
opportunistic infections (Holmes et al., 2006; Lloyd, 1996). 
 
 
PRIOR RESEARCH ON THE IMPACT OF HIV AND ART 
ON LABOUR OUTCOMES 
 
A central theme in the literature that has been built around the 
analysis of the impact of HIV and related treatment of the 
disease in individuals is the decline in health states and/or the 
related loss in productivity building up to dates of separation 
from employment. These separations could be as a result of 
either ill-health early retirements or death. Other possible 
analyses on the effects of treatment on individuals are based 
on the date of first treatment through the use of ART. Whether 
related to employment outcomes, health decline or the effect 
of treatment, the analyses are focused mainly on the patterns 
of observations of various outcome variables around a critical 
event date, which in keeping with the literature, we will refer 
to as date 0. A large motivation for the use of an event date as 
a reference point in which estimations are based around (other 
than that of the date of infection) in the analysis of outcomes 
related to HIV is the vast heterogeneity in the timing of 
disease progression and related asymptomatic period of 
infection. By looking at the patterns around an event date, 
such as separation from employment or date of first treatment, 
one can implicitly control for the varied rates of disease 
progression across patients. The patterns for each individual 
would be similar around death, ill-health retirement, or 
treatment dates regardless of how long it takes for each 
individual to get to the symptomatic stage of the disease in 
which a death, an ill-health retirement, or treatment occurs. 
 
In a seminal paper by Fox et al. (2004), (Kenya) in which tea 
estate employees’ productivity could be directly observed 
through the measurement of the weight of tea leaves plucked 
per day per individual, it was found that there was an increase 
in the number of leave days for an HIV positive worker in the 
three years prior to an AIDS related ill-health retirement or 
death. 
HIV positive employees in the year prior to termination took 
on average around 10 more sick leave days than the control 
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group with a similar difference in the number of casual and 
annual leave days, too. Productivity also declined by an 
average of 17,7% in the year prior to termination. 
 
In a study later conducted by Larson et al. in 2013 (Kenya), 
the authors analysed not only the decline in health states and 
productivity with HIV disease progression but also the 
reversal of this trend following ART initiation. The study 
focused on the same tea estate as that which was reported on 
in Fox et al (2004). The authors used nearest neighbour 
matching techniques in order to match individuals to controls 
in the HIV negative population. It was found that in the month 
of ART initiation, male and female cases plucked 51% and 
62% less tea leaves respectively than the reference group and 
spent on average 47%  and 57 % fewer days plucking leaves. 
After 2 years on ART, male and female cases were on average 
8% and 19% less productive than the matched controls.  
 
Sonnenberg et al. (2011) analysed a large cohort of South 
African gold miners, finding that HIV positive workers in the 
year before death had a 38,8% absenteeism rate. The authors 
also approximate the increased demand for medical services 
by analysing absences due to medical reasons to which a 
13,6% absenteeism rate could be ascribed.  
 
In an early analysis of Anglo American’s HIV treatment 
Programme, Muirhead et al. (2006) looked into the viability of 
public private partnerships in increasing access to ART. The 
authors noted that HIV positive employees took on average 
7,5 sick leave days in the month prior to ART initiation, which 
fell to 2,1 days after 18 months of treatment. 
 
Habyarimana, Mbakile, & Pop-Eleches (2010) use data 
spanning from 2001 to 2006 at the Debswana goldmine in 
Botswana to estimate patterns of per person absenteeism 
around ART initiation dates. They find that HIV positive 
employees take roughly an extra 5 sick days in the month of 
treatment initiation when compared to exactly 12 months prior 
to treatment initiation. Further to this, the authors plot out a  
modelled time path of disease progression in the absence of 
treatment for each treated individual. This estimated time path 
allows for a ‘true’ counterfactual to the treated case to be 
calculated for each individual. 
The discussion and estimations henceforth draw influences 
from the above research, most notably those papers by 
Habyarimana, Rosen and Larson in an attempt to estimate 
patterns of labour and health outcomes around treatment 
initiation dates at Anglo American Coal South Africa. 
 
 
ANGLO AMERICAN HEALTH PROGRAMME 
DESIGN AND MANAGEMENT 
 
As one of the first extensive workplace HIV treatment 
programmes in the world, the Anglo American group of 
companies’ HIV treatment programme design has been well 
documented in the paper ‘Evaluation of a Workplace HIV 
Treatment Programme in South Africa’  (Charalambousa, et 
al., 2007). There have been few fundamental changes to the 
programme design over the years other than the criteria 
stipulating eligibly for HIV treatment, which has advanced 
from a model of that based on CD4 counts and/or diagnosis of 
severe opportunistic infections to a universal test and treat 
                                                        
2 We find that the general rollout of the universal test and treat model appears to have been 
gradually adopted across the company with no clear discontinuity in any specific year of the 
average CD4 count at ART initiation. 
model2. With reference to the prior work by Charalambousa et 
al. (2007), and in further discussion with managers at the 
company, a detailed description of the history and policies at 
the company follows: 
   
A distinction is drawn between the enrolment in the HIV 
programme and HIV treatment uptake. Those diagnosed with 
HIV through a voluntary counselling and testing session are 
offered specialized HIV care through the company. Those 
who opt not to seek care through the company can either seek 
care elsewhere or refuse care entirely. HIV programme 
enrolment offers quarterly health checks which include 
screenings for opportunistic infections, CD4 count checks and 
HIV viral load checks in order to monitor disease progression.  
Although, across the entire sample period, any given patient 
may have become eligible for treatment, treatment uptake has 
always been a voluntary decision for the patient.  
 
Originally the company’s policy, at a patient level, on the in-
house provision of ART was based on eligibility for treatment 
by CD4 count, or diagnosis of severe opportunistic infections 
– those with CD4 counts below 350 cells per millilitre of 
blood were initiated on treatment without further delay. The 
company has since moved to a universal test-and-treat model 
in which anyone diagnosed with HIV becomes eligible for 
treatment as of the diagnosis date.  
There are several motivations driving this strategy.  
1) The proportion of the total additional cost over a 
patient’s lifetime of a universal test-and-treat strategy 
over one based on CD4 counts is minimal. 
2) Waiting for CD4 counts to drop below a threshold 
level puts that person at risk of  
a) waiting too long to test CD4 counts again 
b) increasing the risk of contracting an 
opportunistic infection, such as TB, which would 
then require separate treatment with its own set 
of complications and costs over and above those 
of treating the underlying HIV infection. 
3) Those who initiate treatment at a later stage in HIV 
disease progression are less likely to reach a full 
immunologic recovery (Okulicz et al., 2015; Asfaw 
et al., 2015; Maduna et al., 2015) – a finding, too, 
that is observed in our data set when looking at CD4 
count recovery by CD4 count stratum at ART 
initiation. 
By delaying treatment, it would be expected that the 
patient would be at a higher general lifetime risk of 
contracting any opportunistic infection (Williams, 
Hargrove, & Humphrey, 2010). 
 
While the health and economic impact of HIV/AIDS is well 
documented, and the clinical benefits of antiretroviral therapy 
have been quantified in terms of immune system recovery, 
decline in viral loads and the reduction in HIV related illness, 
the research on labour market outcomes comparing a 
treatment scenario to a theoretical no-treatment scenario in 
non-experimental settings is sparse. Essentially the research 
has looked at the effect of treatment while using the health 
state of each individual at the point of treatment uptake as the 
reference point for post treatment recovery. The effect of 
treatment is seen as the difference in the health state of an 
individual at the point of treatment uptake and the consecutive 
health states subsequent to treatment. While this does still 
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illustrate the benefits of treatment, the depiction of the full 
extent of the benefit will be understated since, mostly, the 
progression of the disease is stopped in its tracks at the point 
of ART uptake. These models do not directly account for the 
fact that there would be a likely deterioration in health from 
the ‘date 0’ had treatment been forgone. An interesting area of 
study, and one we later investigate, is to identify the probable 
health states of individuals had treatment been not been 
initiated at any stage of disease progression – the 




DATA AND METHODOLOGY 
 
 
Our analysis aims to answer the following: How does 
treatment of HIV positive employees with triple combination 
ART affect health-related outcomes within a company’s HIV-
positive portion of their labour force? 
 
This analysis entails, firstly, estimating the effect of treatment 
on the employee’s health related outcomes, and secondly 
projecting employee health states had treatment been refused. 
In order to achieve this, we borrow from the techniques used 
by Habyarimana et al. (2010) with the use of a new sample, 
and in light of the use of more modern HIV treatment 
regimens. We also add insights to the literature on how 
treatment of HIV impacts the length and frequency of clinical 
visits in terms of both inpatient days and outpatient visits – a 
portion of in-house HIV treatment and care which makes up 
for about 50% of the total cost per treated patient at the firm 





The data cover the period from January 2009 to December 
2016 which have been aggregated to monthly measurements 
for each employee for clinical and absenteeism data; with 
annual updates occurring for individual level confounders 
such as marital status, age and job grade on the 1st of January 
each year. All clinical and absenteeism data is recorded on a 
per-incident basis with dates and observations attached to each 
incident for each person, tagged by a system generated person 
ID. The data has been aggregated to a monthly level and 
linked to the extrapolated HR data by person ID and month.  
 
The treatment variable has been manipulated into a categorical 
variable which is able to isolate special treatment cases 
relatively well. 
The categories for HIV specific treatment, which excludes 
other symptomatic treatments, are:  
• Untreated: Those who are HIV positive but have 
never been on ART 
• Treated: Those who are currently on ART 
• Inactive: Those who have been on ART but are not 
currently on ART 
• Own Doctor Treating: Those who have foregone 
company treatment and opted to get “treatment” 
elsewhere3.  
 
                                                        
3 Since this is a self-reported variable, we cannot be sure of the legitimacy of the external 
treatment. In some cases, patients seeking traditional or cultural treatment may report to have 
opted for external “treatment” not in the form of ART. 
The data contain 12 035 unique person observations, of which 
5 072 (42,14%) of the people remain in the panel across the 
entire observational period. 75% remain in the study window 
for at least 47 months. The average employee count over the 
years is roughly 8 900. We observe 1962 separate cases of 
HIV positive employees either from the start of the window or 
from some point during the window of observation. 47% of 
the people who have been or will be diagnosed with HIV at 
any point during the study remain employed at the company 
for the full time period under study, with 75% of this sample 
remaining employed for at least 54 months. Over the 8 year 
window there were 583 879 illness related absenteeism 
incidents, 184 684 outpatient visits and 11 212 inpatient days 
recorded. There were 1 243 separate treatment initiations 
across 1 028 HIV positive employees who have initiated 
treatment during the sample period, of which 880 are first time 
treatment initiations. A group of 932 patients has reported 
complete adherence to their treatment regimen during their 
time at the company (which may extend beyond the sampling 
window). Treatment initiations across the sample window are 




With the introduction of the HIV treatment programme, policy 
stipulated CD4 counts were to be tested on a quarterly basis 
for those who had enrolled in the programme. An average 
duration between clinical tests of 3.6 months was observed in 
2009 with a general upward trend in the length between tests 
to 5.7 months in 2016, as the company deemed the quarterly 
frequency of tests to be excessive for clinical monitoring 
purposes in most cases.  
For certain estimations, we use linear interpolation in order to 
populate missing CD4 counts between tests.  
The treatment initiation date and the HIV programme 
enrollment date need not necessarily coincide -  a median gap 
of enrollment in the HIV programme (which includes clinical 
tests but not necessarily treatment) to first treatment initiation 
of 13 months is seen in the data.  
 
The distribution of CD4 counts at ART initiation has slowly 
shifted rightwards over the years, due mainly to the steady 
adoption of more relaxed treatment eligibility criteria. 
The gradual upward shift in the proportion of ART initiations 
at higher CD4 counts is documented in figure 4. Group B, the 
percentage of those initiated on ART prior to progressing to a 
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cells/mm3), has increased drastically since 2013, while those 
in group A, those initiated on treatment only after progressing 
to an advanced level of immunosuppression has dropped to 
about 13%. The greatest area of growth in the proportion of 
initiations is in the CD4 stratum of >600 cells/mm3 at first-
time ART initiation, while those initiated at a CD4 count of 
less than 50 has fallen to 0%. 
 
There has been a paradoxical increase in the HIV prevalence 
rate of the tested at the company since the implementation of 
the programme. This is due in part to higher test rates, 
resulting in more accurate estimations of the population 
prevalence rate over the years as well as being an artifact of 
treatment itself – fewer deaths with somewhat stable new 
infection rates result in higher prevalence rates. The HIV 










Although the statistical causality of the relationship between 
HIV treatment and TB incidence at the company is yet to be 
established, the remarkable decline, by more than 2 thirds, of 
newly diagnosed TB cases is somewhat of a medical marvel 
warranting further research into the topic.  
 
                                                        
4 Test rates and prevalence rates by year may be found in the appendix 
5 We restrict the regression to HIV positive employees with observed CD4 counts. This does 
introduce a form of bias in that those HIV-positive patients diagnosed with TB will, as a matter 
of policy, be urged to test their CD4 count, while those without a recent TB diagnosis are not 
Although not central to the paper, we depict briefly the 
relationship between CD4 counts and incident TB, what could 
be loosely be inferred as a proxy for all opportunistic 




























likely to be presented with the same urgency to test CD4 counts. We would find higher CD4 
test rates across samples with active TB than across samples without active TB. Despite the 
possible overall bias, we would expect the general trend to remain regardless of the possible 
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ESTIMATION AND MODELING  
 
 
The Problem of Estimating Treatment Effects in the 
Presence of Strong Selection into the programme as well as 
HIV treatment uptake: 
 
At the heart of this analysis lies a company treatment 
programme in which treatment uptake, although now 
encouraged at every stage of HIV progression, is an entirely 
voluntary decision for the patient.  
Estimating the treatment effect of the programme is also 
severely complicated by aspects internal to the company, such 
as the fact that, originally, eligibility for treatment was 
determined by either a threshold CD4 count which is a strong 
determinant of the progression of the disease, or for those who 
had already contracted a severe opportunistic infection such as 
TB. This resulted in, generally, asymptomatic HIV-positive 
employees making up the majority of the untreated group, 
while the treated group would be those who were already 
presenting with symptoms of immunosuppression around the 
treatment initiation date, thus creating a substantial treatment 
uptake selection bias. Beyond the selection into treatment 
from the company’s side, in the earlier years of the 
programme, and even after the treatment eligibility was 
extended to all HIV positive employees regardless of disease 
progression, it would not be unreasonable to assume that the 
potential adverse side effects of treatment, the introduction of 
potentially time consuming daily routines, or the pure stigma 
of HIV could result in HIV positive people in the very early 
stages of disease progression delaying treatment until the 
perceived health benefits of treatment outweighed the 
perceived costs. We speculate that selection bias thus arises 
from both the company’s side as well as the patients’ sides. 
Even once possible selection bias is controlled for based on 
observables such as pre-treatment CD4 counts, viral loads and 
time since diagnosis which would directly affect health 
outcomes, the decision to initiate treatment from the patient’s 
side at any stage would still, essentially, be a behavioural 
phenomenon which is difficult to directly observe. With this 
possible behavioural link, and as with the correlation between 
lifestyle choices and HIV infection (Robles et al., 1994) or 
willingness to test for HIV (Bärnighausen, Bor, Wandira-
Kazibwe, & Canning, 2011), those who choose not to enroll 
into the programme could be the ones with lifestyle choices 
that also adversely affect health outcomes unrelated to HIV 
infection, and, consequently, could also affect our outcome 
variables. 
We look to solve part of the problem of selection by 
restricting our analysis to only those patients who have opted 
for treatment at any stage during our 8-year sample window, 
while disregarding those HIV positive employees who are yet 
to initiate treatment. The panel structure of our data allows us 
to observe, across time,  any patient meeting our sample 
selection criteria in the months prior to and following 
treatment uptake – a untreated and subsequently treated state. 
This will allow us to estimate the dynamics of health and 
health recovery prior to and following treatment uptake  
It is worth noting, however, it would be expected that there 
would be disparate effects of treatment on viral loads, CD4 
counts, days absent, as well as inpatient days and outpatient 
visits contingent on the stage of disease progression at 
treatment uptake (Asfaw et al., 2015). On the two extreme 
ends of the spectrum, those who initiate treatment at a late 
stage are likely to see a drastic and prompt recovery from their 
current health state (barring the paradoxical phenomenon 
known as immune reconstitution inflammatory syndrome 
(IRIS) in very late stage AIDS patients), yet those who initiate 
treatment at a completely asymptomatic stage are likely to 
benefit only from the fact that there will not be a decline in 
their already adequate health state following treatment 
(Sharma & Soneja, 2011; Maduna et al., 2015). 
In light of this, we will discuss two possible concepts around 
the effect of treatment in our analysis.  
1) The average effect of treatment as it stands at the 
company for the pool of people who initiated ART at 
the observed levels of disease progression. 
2) The average difference between the observed treated 
states of the individuals following treatment and the 
modeled state that would have been observed had 
treatment been forgone. 
 
 
As a first pass approach, we adopted matching techniques in 
order to identify this counterfactual - finding suitably similar 
people based on conditions around treatment uptake, disease 
progression, or time from infection, while controlling for other 
factors, and differing only in that of treatment status. In this 
way, we could use the untreated person as a theoretical 
reference case for what would have happened to the treated 
patient in the absence of treatment. However, we find, 
especially in this sample, a distinct lack of untreated patients 
who could be identified as being a match to a treated patient in 
the treated patient’s treatment initiation month and then 
subsequently staying untreated for a long enough period of 
time to observe the true difference between treated and 
untreated cases. It is also a possibility that the patients who are 
assign themselves to the untreated control may never progress 
to a point of immunosuppression in which they would justify 
treatment during our sample period. The complexity of this is 
brought about mainly as an artifact of the disparity observed 
in time to disease progression across patients. The matched 
untreated controls will generally opt for treatment the moment 
a severe enough random health shock is experienced - 
otherwise all that is observed over time in our control is an, 
essentially, asymptomatic HIV-positive patient with a similar 
CD4 count and time since diagnosis as the treated patient, as 
measured at the treated patient’s ART initiation month.  
As an intuitive method, we opt, instead, to attempt to model 
theoretical disease progression in the absence of treatment for 
each treated patient as of each patient’s treatment date based 
on observed disease progression prior to ART uptake, as well 
as on external clinical studies on disease progression based on 
CD4 counts. This would allow for a counterfactual to the 
treated case to be estimated, while explicitly modeling the fact 
that, had treatment been refused, the health state of the treated 
patient would likely decline from that of the observed health 
state as is measured at the point of treatment initiation. 
 
Adopted Modeling Approach: 
 
Following in the style of Habyarimana et al.  (Habyarimana, 
Mbakile, & Pop-Eleches, 2010), the average impact of the 
provision of antiretroviral therapy on the number of sick days 
taken by an HIV positive employee in any given month will 
be modeled primarily on the number of months prior to and 
following treatment uptake, while controlling for both month 
and year time trends independent of the controls for the 
months from treatment. We also include an array of controls 
for observable individual level confounders.  
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Additionally we look to control for unobservable individual 
characteristics and sample attrition using a combination of 
fixed effects models and inverse probability weightings of 
sample observations in separate models. 
 
The estimation differs in that of the estimation of 
Habyarimana et. al. as those who are not in the pool of people 
who have been or will be diagnosed with HIV are left out of 
the estimation (ie. We look only at those who are consistently 
HIV positive across the sample window). This will, in effect, 
show the correlations between sick days, as well as inpatient 
and outpatient days and the dependent variables for only the 
HIV positive pool in our dataset, which is our primary sample 
of interest. Part of the distinctiveness of this data set is that it 




We model our outcomes on the general estimations which will 
be determined by the following functional form, estimated by 
OLS: 
 
1) !"# = 	&' + ∑ *++ ,-./ℎ1_34-,_567_1/84/"#
+ +
∑ &99 :;41-.<=>#?=@"#







!"# = number of Illness related absenteeism events per month, 
 
estimation 2)  
!"# = number of inpatient days per month  
 
estimation 3) 
!"# = number of outpatient visits per month 
 
and common to all estimations: 
,-./ℎ1_34-,_567_1/84/"#
+  = indicator variable for each 
month, j Î [-11; 12], from the treatment initiation month for 




9  = each person control, k, for employee i at 
time t.  
k = {gender, age, age2, marital status, employment band} 
 
,-./ℎ"#
B  = indicator variable for each month of the year,  
h Î [2; 12], for employee i at time t, where the base month has 
been set to January. 
 
!;84"#
D = indicator variable for each year, p Î [2010; 2016], 
for employee i at time t, where the base year has been set to 
2009. 
 
E"#  = the error in estimation for person i at time t. 
 
 
Sample attrition  
 
Beyond the obvious sample selection problems brought about 
by such voluntary treatment uptake programmes, we explore 
                                                        
6 We look purely at first round initiations due to the fact that there is no reliable way to have a 
single measure of the months from treatment initiation in a case where someone has stopped 
treatment and then started again. A person who stops first time treatment after five months and 
the possible attrition of our sample of those who have opted 
for treatment (those who have started treatment and 
subsequently discontinued treatment after any given number 
of months) which could potentially introduce yet another 
source of bias.  
The concern that attrition in our sample, and the associated 
missing data from lost participants, could be fundamentally 
correlated with absenteeism, inpatient days and outpatient 
visits creates a scenario in which it is worth looking at 
separation patterns within the sample. Conceptually, the 
sickest people are most likely to fall out of the sample due to 
ill health retirements or death, and had these people remained 
in the sample, would have likely had a heavy weight on the 
average observed values of the outcome variables. Looked at 
from another point of view, the healthiest individuals 
following treatment, for which ART has been wholly 
effective, may be of the opinion that they need not continue 
treatment. These patients could conceptually bias the results of 
our estimations in the opposite direction as previously 
discussed by dropping out of our sample of treated patients.   
Ideally, we seek a scenario in which those contributing to the 
attrition in our sample are dropping out randomly and not due 
to some relationship with their health state at the point of 
separation. 
 
In figure 5, we consider the possible impact sample attrition 
could have on our analysis - not as a measure of true treatment 
attrition rates at the company. The attrition patterns are 
depicted purely for those who are used in the sample in the 
identification of our regression model.  
The attrition rates shown in figure 5 are split into groups of 
those who have stopped first round treatment for any reason, 
be it non-adherence, adverse reactions etc., and those who 
have fallen out of the sample/left the company due to ill-
health-retirements or death. These attrition rates are geared 
directly at first time initiations, regardless of whether 
treatment is then started at a later date in the form of a second, 





The total attrition, attributable to any scenario, of participants 
undertaking first-time treatment in this sample is around one 
in four patients after 3 years, with a steady decline in the rate 
of attrition the greater the length of time from first treatment 
then starts treatment for a second time 10 months after starting the first time could be considered 
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uptake7. The total attrition rates are similar to those observed 
in Habyarimana, yet those due to ill health or death seem to be 
considerably lower, which lies at 4% as opposed to 12% after 
3 years The result provides some relief that this may not be as 
large of a concern in causing significant sample attrition bias.  
 
On the other spectrum of the discussion on attrition, we do not 
allow for replenishment within the sample. Those who would 
be replenishing the sample are those who would be initiating 
second, third or fourth round treatment. The interaction 
between months from first treatment and that of subsequent 
treatment initiations and the related influence on health status 
is hard to theorize in this scenario since the outcome is based 
largely on the situations surrounding treatment termination. 
We assume the “best case” scenario by limiting our sample to 
those of whom have reported complete adherence to treatment 
for at least 12 months following first round treatment 
initiation.  Adding to the former issue is that any individual 
stopping treatment for any reason and then starting treatment 
at a later date can be considered to be both a positive number 
of months from first treatment and a negative number of 
months from second treatment, where both first and second 
time treatment initiations are considered as date 0 (treatment 
initiation month). We thus exclude any patients without a 
reported 100% adherence to treatment8. 
 
 
The estimations describing the underlying relationship 
between months from treatment uptake and our outcome 
variables, monthly sick days, inpatient days, and outpatient 
visits, are run using an array of functional forms for 
comparison of the robustness of the estimates.  
 
Due to the fact that the decision to seek treatment could be 
highly correlated with individual level behavioural 
characteristics, such as levels of risk aversion, which may also 
impact absenteeism unrelated to HIV-related events, an 
individual fixed effects model is fitted to control for 
unobservable characteristics, over and above the controls for 
the observable time variant factors.  
In the spirit of Habyarimana et. al. we break the analysis down 
into one in which an unbalanced panel is used with and 
without fixed effects, a balanced panel and, finally, a model 
using inverse probability weights in order to control for 
sample attrition and the possible bias this may introduce. 
 
In our use of the inverse probability weighting of sample 
observations, where an assumption is drawn that those who 
stop treatment for any reason, whether it may be death, ill 
health (and separation from the company) or treatment non-
adherence, do not do so randomly and that attrition is 
fundamentally correlated with the outcome variables. The 
inverse probability weighting will, to some extent, control for 
any attrition bias that may be present. We are assuming that 
when estimates are conditioned on the inverse of the 
probability, based on observables, of someone dropping out of 
the sample, any attrition and related missing data will be a 
random occurrence, such that the ignorability assumption is 
satisfied (Weuve et al., 2012; Wooldridge, 2002, 2007). 
 
The probability weights for each employee for the IPW 
estimation are calculated as of the date of first treatment 
initiation based on the probability of the programme 
                                                        
7 Separations for the total company, both HIV negative as well as positive sits at around 15% 
after 3 years. 
participant leaving the treatment programme within 12 months 
of the first treatment start date. Those who have a high 
probability of leaving the programme based on observable 
characteristics at date 0 and yet stay in the programme for at 
least 12 months are given a higher weight in order to 
compensate, in a way, for the attrition in the sample that can 
be attributed to the factors included in the probability model 
and that would otherwise bias the results.  
The probability model does not look at the factors influencing 
the participant having been observed in the months prior to 
treatment – this would be purely based on how long the 
participant had worked at the company prior to treatment 
uptake, and not necessarily as a result of the magnitudes of 
any of the outcome variables, since all programme 
participants would have observations of both independent and 
outcome variables if they had been at the company for at least 
12 months prior to treatment initiation.  
 
We specify a likely probability model for use in calculating 
our probability weights, based on patients’ health states at 
treatment initiation and using the employees’ genders, marital 
statuses, job grades, a quadratic in age and maximum tenure at 
the company as of treatment initiation, as well as the month 
and year of treatment initiation and starting CD4 count. The 
number of times a person has left and rejoined  
the company seems a likely descriptor of the probability of 
leaving the sample at the moment of treatment uptake, 
however, there is a perfect correlation between leaving the 
sample within 12 months and having previously left the 
company, we are thus required to exclude this descriptor from 
the estimation of the probability weights.  
The exact specification, estimated at the point of treatment 
uptake, using maximum likelihood, is as follows: 
 
G-HI/(:") =	&' + ∑ &99 :;41-._F-./4-G"
9 +
∑ ABB ,-./ℎ"









9 = the vector of individual level controls for 
person i, 






B =  indicator dummy for the month in which treatment 
was initiated for patient i 
h Î [2;12] 
 
!;84"
D = the year in which treatment was initiated for each 
patient i 
p Î [2010;2016] 
 
E" = the error in estimation for person i at time t. 
 
 
Results and Discussion: 
 
8 There will almost always be a disparity between reported and actual adherence. Despite this, a 
recorded treatment termination due to patient non-adherence is what would trigger an official 
failure of a first time treatment initiation in our analysis. 
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The results of the various estimations are presented in table 1 
for the impact of ART on sick days. Although also discussed 
in this section, the estimations for the impact of ART on 
inpatient days and outpatient visits may be found in the 




The coefficients of the dummy variables of months around 
treatment initiation show, prior to the initiation date, the 
estimated disease progression in terms of its effect on sick 
days, inpatient days and outpatient visits, and following 
treatment, the estimated effect of ART over time while 
controlling for other factors which may influence the outcome 
variables of interest. Statistically insignificant coefficients of 
any particular month from treatment suggest no marginal 
impact above the reference month, 12 months before 
treatment, which, given the progression of CD4 counts 
previously illustrated we could consider to be a point in which 
patients would present with few symptoms of 
immunosuppression. We observe statistically insignificant 
impacts of most of the months building up to treatment 
initiation date which coincides with the asymptomatic period 
of disease progression. In the four to five months before 
treatment initiation, we observe a noticeable increase in the 
number of sick days, inpatient days and outpatient visits. All 
three of these variables peak in the month of treatment 
initiation, again confirming the large degree of selection into 
treatment.  The marginal impact of treatment in the months 
following treatment initiation is drastic, with a reduction in 
sick days, on average, of one day per month, additively, for 
each of the first three months following treatment, with further 
yet less pronounced improvements in health for up to 10 
months following treatment initiation.  
Delving further into the trends revealed by this regression, we 
present in the appendix the results of the above regression, 
stratified into 3 groups by CD4 count at ART initiation. We 
find that the broad patterns around the treatment initiation date 
are remarkably similar across the strata yet with more 
pronounced effects in only the magnitude of changes for lower 
CD4 strata at ART initiation. What we would find in plotting 
these changes in health states around treatment is 3 nested  
 
curves, with the group of the lowest CD4 counts displaying 
the greatest magnitudes in changes. 
 
 
After progressively rising from statistically insignificant 
values in the 4 months prior to initiation, inpatient days fall 
from a peak average across the sample of 0,6 days in the 
treatment month to statistically insignificant values after 4 
months. 
Outpatient visits, the dynamics of which are slightly different 
to those of sick leave and inpatient days since outpatient visits 
can, at any stage, be attributable to non-illness related visits 
(such as renewal of scripts for chronic medication), reach a 
peak of 3,5 visits per month in the treatment month, however 
remain at just under one visit per month on average even after 
full recovery. This can presumably be ascribed to checkups 
relating to patient treatment adherence, general health, and 
Although the above specifications illustrate the effect of 
treatment on those who opt into the programme, they do not, 
in any way, depict what would have been the outcome had the 
patient, at the time of treatment uptake, been refused, or, 
themselves, refused treatment. We have a fundamental issue 
in that the estimations of treatment effects on the treated 
sample is exactly that – estimations for a treated sample. The 
greatest area of interest, however, when modeling the full 
benefit of treatment is to depict the outcomes in a case where 
treatment was not given at the time each person in our sample 
was, in the reality, initiated on ART.  
We look to address this issue by modeling a plausible path of 
disease progression, in the absence of treatment, in the form of 
CD4 decline for each patient at the point of treatment 
initiation and beyond, and subsequently mapping clinical 
disease progression to each of our outcome variables. 
 
Table 1 
  Sick Days Sick Days (Unbalanced Sample) Sick Days (Balanced Sample) Sick Days (IPW Estimation) 
          
Fixed Effects N Y Y Y 
11 months before treatment -0.00996 -0.000973 0.0994 0.114 
10 months before treatment -0.0290 -0.0118 0.103 0.0851 
9 months before treatment 0.0744 0.0980 0.175 0.107 
8 months before treatment 0.131 0.160 0.0963 0.0446 
7 months before treatment 0.187 0.228 0.191 0.221 
6 months before treatment 0.154 0.204 0.212 0.218 
5 months before treatment 0.415* 0.473** 0.566** 0.505* 
4 months before treatment 0.597*** 0.650*** 0.842*** 0.787*** 
3 months before treatment 0.687*** 0.752*** 1.081*** 1.168*** 
2 months before treatment 1.062*** 1.142*** 1.527*** 1.889*** 
1 month before treatment 1.816*** 1.913*** 2.326*** 2.574*** 
Treatment initiation month 4.757*** 4.873*** 5.308*** 5.797*** 
1 month after treatment 3.175*** 3.290*** 3.902*** 4.455*** 
2 months after treatment 1.898*** 2.025*** 2.299*** 2.408*** 
3 months after treatment 1.277*** 1.413*** 1.829*** 1.752*** 
4 months after treatment 1.068*** 1.215*** 1.593*** 1.412*** 
5 months after treatment 0.915*** 1.072*** 1.333*** 1.191*** 
6 months after treatment 0.795*** 0.961*** 1.110*** 1.020** 
7 months after treatment 0.505** 0.682** 0.926*** 0.718 
8 months after treatment 0.634*** 0.822*** 1.145*** 1.024** 
9 months after treatment 0.454** 0.653** 0.983*** 0.857* 
10 months after treatment 0.218 0.422 0.449 0.542 
11 months after treatment 0.328 0.537* 0.822** 0.629 
12 months after treatment 0.285 0.499* 0.758** 0.582 
          
Observations 20,929 20,929 13,539 18,567 
R-squared  0.063 0.073 0.094 
Number of unique id 1,001 1,001 500 799 
 
*** p<0.01, ** p<0.05, * p<0.1     
Notes: 
Each of the above specifications contain controls for month and year time effects distinct from the variable measuring time from treatment uptake, other controls include a quadratic of the patient’s age, and in the case of 
the non-fixed effects regression, gender, job grade and marital status.  
Similar regressions covering the analysis of inpatient days and outpatient visits may be found in the appendix to this paper. 
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CD4 modeling and Counterfactual estimates for 
Sick days in the absence of treatment: 
 
The fundamental issue faced when looking for treatment 
effects in this analysis is the lack of a suitable statistical 
counterfactual. We attempt to model the theoretical no-
treatment scenario for each treated patient by mapping disease 
progression, in the decline of CD4 cells in the absence of 
treatment, to absenteeism data. We will, in this way, be able to 
plot out a probable time path of sick days in the absence of 
treatment following the actual observed treatment date of each 
patient. This method does not come without its issues – chief 
among which is the fact that we are essentially attempting to 
fit a model using estimates we are assuming to have sufficient 
external validity to extrapolate values of CD4 decline into our 
data set, and again using a best guess at the relationship 
between CD4 counts and sick days. CD4 counts in level form, 
although highly correlated with absenteeism can only explain 
roughly 6% of the variation in sick days. Since the CD4 count, 
beyond the month and year controls, is the only variable we 
are predicting a time path for in our model, we are assuming 
that this is the primary mechanism driving the dynamics of the 
incidence of sick days – a somewhat unrealistic assumption.  
In spite of the troubles of using this technique, it nonetheless 
provides plausible estimates of the time to death from what we 
will call the theoretical “refusal of treatment date”, date 0. 
Providing encouragement for this technique is the fact that the 
estimates are not out of line from what previous literature 
investigating health deterioration of HIV positive patients 
would predict. Further to this, the estimates of the progression 
of sick days would seem to be, if anything, understated when 
compared to the time path of in-sample sick days prior to 
treatment.  
 
In order to model CD4 count decline from the date of 
treatment in the theoretical case of the person not having 
opted to initiate treatment, we use the nearest CD4 count prior 
to treatment in order to estimate the CD4 count at date 0 
should the last CD4 test date not be in the same month of 
treatment uptake. Generally speaking, and in the earlier years 
of the programme, CD4 counts were the trigger for treatment 
initiation, or, at the very least, testing of CD4 counts had and 
continues to have a high enough correlation with treatment 
initiation as to have programme participants’ CD4 count tests 
in the month of treatment, or in the one or two months prior to 
treatment initiation. This relationship has bidirectional 
causality. Our strategy of interpolation is thus expected to 
yield more or less accurate estimates of CD4 counts in the 
month of treatment. Nonetheless if there is a treatment 
initiation date prior to which, the nearest CD4 count 
observation is greater than 3 months from the date, we exclude 
the estimate from our interpolation strategy. The relationship 
between disease progression and health outcomes such as viral 
loads and CD4 counts is well documented in the medical 
literature (Dunn, 2006; Hogg, 2001; Holmes et al., 2006) with 
evidence pointing to an average decline of 12 CD4 cells per 
month for those with CD4 counts below 300 cells in the 
absence of treatment (Jaffar et al., 1997; Morgan et al., 2002). 
As depicted in table 2, the average CD4 counts for our sample, 
at ART initiation prior to 2015, falls within an acceptable 
range of the 300 cells/mm3 baseline for us, for the most part, 
to expect the sample to adhere to similar dynamics of CD4 
decline. Although the 2016 initiations fall far from the 300 
cell mark, the vast majority of these patients will not make it 
into our sample, since we previously stipulated the 
requirement that there be 12 months’ worth of observations 




Mean CD4 Count at ART Initiation by year 
2009 209.3503 2013 237.0396 
2010 241.9107 2014 295.0774 
2011 214.9615 2015 387.9898 
2012 232.1667 2016 428.4242 
Table 2 
The relationship between disease progression and sick days/ 
productivity has been documented in ‘The Impact of 
HIV/AIDS on Labour Productivity in Kenya’  (Fox, et al., 
2004). Although we could use the aforementioned results 
directly in the modeling of sick days in the absence of 
treatment, we opt for the more indirect approach of first 
parameterizing a model based on the relationship between our 
outcome variables and patients’ CD4 counts, following which, 
we extrapolate CD4 counts beyond the treatment date using 
the expected CD4 decline in the absence of treatment, and 
subsequently employ the aforementioned models to obtain a 
simulated counterfactual. We expect this method to have 
reasonable internal validity. This approach also allows us to 
maintain consistency in our modeling of sick days, inpatient 
days and outpatient visits.  
This is not an ideal scenario since we would prefer to model 
the total treatment effect based on an ‘observed’ 
counterfactual, however this is generally not possible.  
The span of the asymptomatic period of the disease can differ 
drastically between patients. To observe a possible alternate to 
a treated patient we would require that an untreated patient be 
similar in all attributes other than their decision to be treated. 
These patients in this setting are few and far between, since 
there is such high treatment uptake. Beyond this, the 
measurement of CD4 counts, one of the best predictors of 
disease progression as well as being the best matching 
variable in this dataset, is also highly correlated with 
treatment. We find that the untreated sample has fewer CD4 
measurements in which to use to match to a treated patient.  
 
Despite the challenges of modeling a counterfactual by 
employing the method that follows, our model does yield 
highly plausible results and is generally in line with what we 
would expect in terms of survival rates as well as the general 
decline in health and associated increase in monthly sick days 
over time (Bor, Tanser, Newell, & Bärnighausen, 2012;  
Charalambous et al., 2007, 2007; Fox et al., 2004;  Meyer-
Rath et al., 2012; Mocroft et al., 2007; Sonnenberg et al., 
2011).  
 
We diverge from the modeling of a panel fixed effects 
regression for the estimation of the relationship between CD4 
counts and sick days, inpatient days and outpatient visits since 
the coefficients of the time invariant factors are required for 
the prediction of the outcome variables which the fixed effects 
model would difference out. We control for as many relevant 
observables as possible, however, a limitation of this is that 
regardless of how comprehensive the variable list is we cannot 
control for unobserved behavioral mechanisms that may be 
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We use a cubic function in CD4 counts9, a quadratic in age 
and consecutive months worked, indicator variables for the 
year and, separately, month of the year, gender, marital status, 
and worker band. 
The results of the linear regression depicting the relationship 
between that of sick days taken per month and CD4 counts are 
presented below (Table 3). We use the entire HIV positive 
sample in this estimation, which is why there is a jump in the 





The above results are particularly sensitive to the use of 
imputed values of CD4 counts, most probably due to the fact 
that the measurement of CD4 counts is likely correlated with 
CD4 counts themselves. The measured CD4 test observations, 
or lack thereof, in a standard regression would result in a 
regression based purely on those patients who needed a CD4 
count test in the first place in that particular month. Although 
there are a multitude of factors that could prompt such a test, 
of which some are mostly unrelated to the observed health 
state of the individual, other reasons that would trigger 
medical staff to test CD4 counts in HIV positive patients 
would be the possible diagnosis of opportunistic infections. 
Thus, missing CD4 counts in our data would not be missing at 
random. To address this, for the most part, we use linear 
                                                        
9 Missing values are imputed using linear interpolation between any two consecutive 
measurements of CD4 counts for each person. On average there are between 3 and 4 imputed 
values for CD4 counts in the months between any two actual measurements of CD4 counts. 
interpolation to fill missing observations between any two 
CD4 tests. As with papers by Habyarimana et al. (2010) and 
Meyer-Rath et al. (2015) we assume the linear prediction of 
CD4 counts between observations is a more or less accurate 
approach in dealing with missing values. We  
 
We account for weekends and public holidays in the analysis, 
giving the maximum possible number of sick days as the 
number of work days in each month. We assume death occurs 
at CD4 counts less than 30 cells, resulting in 100% sick leave. 
The average CD4 count at the treatment date for those 
initiating treatment is 253 cells/mm3 with a standard deviation 
of 160 cells/mm3. We find that, had each patient not initiated 
treatment, 75% of the group initiated on treatment would be 
dead after 25 months, and the entire HIV positive workforce 
would be dead within 51 months had they forgone treatment.  
This is in contrast to the Habyarimana paper in which it is 
calculated that all enrolled workers would be dead within 26 
months from date 0 had treatment been foregone. We can 
attribute this difference to earlier enrollment in the programme 
in the Anglo case. 
 
Across figures 7-10, we depict, graphically, the results of our 
modeled counterfactual outcomes. We include representations 
of the counterfactual in CD4 decline in the absence of 
treatment as well as the implied increase in the amount of sick 
leave taken relative to the case in which treatment was 
initiated. 
 









    
*** p<0.01, 
**   p<0.05, 
*     p<0.1 
CD4_Count -0.0194***  
CD4_Count2 2.18e-05*** 
CD4_Count3 -7.13e-09*** 
month = 2 -0.0141  
month = 3 0.124  
month = 4 0.0706  
month = 5 0.269*  
month = 6 0.306*  
month = 7 0.731***  
month = 8 0.359**  
month = 9 0.478***  
month = 10 0.447***  
month = 11 0.212  
month = 12 -0.170  
year = 2010 0.0697  
year = 2011 0.123  
year = 2012 0.523***  
year = 2013 0.705***  
year = 2014 0.396***  
year = 2015 0.424***  
year = 2016 0.274*  
Gender = Male -0.123  
Marital Status = 
Single -0.00847 
 
Current Age -0.00632  
Current Age2 1.10e-05  
Constant 5.942***  
      
Observations 18,054  
Number of id 2,164  
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We calculate the treatment effect for the individuals for each 
consecutive month following treatment uptake as the 
difference between the actual sick days post treatment and the 
modeled sick days for that individual based on CD4 decline 
had treatment been refused. Figure 7 shows the changing 
treatment effect as the distance from treatment grows. The 
greatest change in the treatment effect is in the first few 
months following the treatment date where those initiated on 
treatment display a drastic recovery while the modeled no-
treatment case shows a slow and steady decline in health. The 
predicted treatment effect stabilizes as the treated reach pre-
illness health states while the modeled non-treated sample 
continues its steady decline. Our modeled treatment effect is 
calculated in such a way that it displays the dynamic nature of 
disease progression in a way that most other papers omit.  
We can depict both the gradual recovery of the treated relative 
to the treatment date as well as the gradual decline in health of 
the modeled untreated and the widening gap between the two 
states over time from date 0. 
 
The total treatment effect over n months is calculated as the 
cumulative difference between the treated and untreated states 
for each person up to month n – Essentially the integral of the 
graph of the per patient difference in sick days between 
treated and untreated cases.  After 36 months from the true 
treatment date, we estimate that, had treatment been forgone, 
the untreated patient would have taken a total of roughly 250 





Although the results presented paint a strong picture that are 
of interest to policy makers, the limitations introduced by the 
non-random selection of the data in the form of looking purely 
at those with full adherence would suggest a difference in true 
overall policy outcomes. Disregarding patients who have 
disrupted treatment at any stage is considered to be weakness 
of this analysis. Further work could look into the outcomes for 
all adherence groups. 
Non-random missing instances of missing data that could, 
intuitively, be correlated with health outcomes introduces 
another possible source of bias – those with missing CD4 
count measurements could be those who feel healthy enough 
to justify missing a health checkup to themselves, or otherwise 





The patterns of absenteeism around the date of ART initiation 
depict the rapid progression of HIV and related 
immunosuppression in the months building up to treatment 
dates. The increase in absenteeism, inpatient days and 
outpatient visits can all be related to the decline in CD4 counts 
which, across all CD4 strata, reach their minimum in the 
month that treatment is initiated.  
Although CD4 counts recover post treatment across all CD4 
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counts have persistently lower CD4 counts for many years 
following treatment.  
Treatment programmes would benefit from a faster rollout of 
‘universal test and treat’ strategies in this regard. 
 
We find that the reduction in sick days, on average, for those 
initiating treatment is most drastic in the first 3 months 
following ART initiation. Compared to the incidence of 
absenteeism attributable to the distance from treatment 
initiation, patients take on average 3 fewer sick days per 
month than in the month of treatment uptake. After the first 
year on ART, patients take on average 4,5 fewer sick days per 
month than in that of the month of treatment uptake. 
 
Patterns of inpatient days around treatment uptake display 
similar dynamics to that of absenteeism in that they rise 
steeply in the 4 months prior to treatment uptake and drop off 
rapidly in the first 3 months following treatment. The demand 
for healthcare resources at the company can be well 
approximated by these figures. As with the relationship 
between TB incidence and CD4 counts, the majority of 
inpatient visits can be attributed to patients initiating ART at 
more advanced stages of immunosuppression.  
 
Outpatient visits, unsurprisingly, peak in the month of 
treatment initiation before falling and then stabilizing at 
around 1 visit per month. These visits can be attributed to 
follow ups and script renewals.  
 
The benefits of antiretroviral therapy for HIV positive 
individuals in terms of decreased mortality, morbidity as well 
as an increase in quality of life has broader effects for 
company efficiency. The management of employee health can 
be and should be equated to any other programme aimed at 
increasing the efficiency of company operations. 
The effective management of health, of which the 
management of HIV plays an increasing role in Southern 
Africa, has net benefits for employee productivity.  
The cost of treatment and care for HIV patients has dropped 
so substantially in the last decade that the strategy of 
providing this medication free of charge to employees could 
be cost saving, even in the absence of much deserved public-
sector subsidies.  
 
The benefits for large companies, at a micro level, of the 
implementation of HIV treatment and care strategies, if 
allowed to permeate to small and medium enterprises, too, 
could potentially have spillover effects that extend far into the 
macro economy.  
 
Antiretroviral therapy has given HIV positive people a second 
chance at living healthy lives. Beyond the benefit to the 
individuals, businesses share in the value created by the 
provision of this life changing medication to their workforces.  
Businesses must learn to be proactive in fighting a disease 
whereupon its demise will be completely determined by both 
the public and private sectors’ response to an epidemic which 


















                                                        
10 Although omitted from the output, the regressions on inpatient days and outpatient visits 
contain the same controls as specified in the body of the paper in the regression on sick days  
            
VARIABLES 
total_inpatient_days 








          *** p<0.01, ** p<0.05, * p<0.1 
Fixed Effects N Y Y Y  
11 months before treatment 0.0564 0.0573 -0.00870 0.0194  
10 months before treatment 0.0349 0.0372* 0.00577 0.0180  
9 months before treatment 0.0163 0.0205 0.0116 0.00542  
8 months before treatment 0.0221 0.0276 -0.0108 -0.00214  
7 months before treatment 0.0310 0.0395 -0.0114 -0.0114  
6 months before treatment 0.0278 0.0378 -0.00802 -0.0127  
5 months before treatment 0.00871 0.0220 0.00115 -0.00941  
4 months before treatment 0.105* 0.121*** 0.114** 0.0860  
3 months before treatment 0.156*** 0.175*** 0.244*** 0.182**  
2 months before treatment 0.157*** 0.180*** 0.218*** 0.181***  
1 month before treatment 0.308*** 0.337*** 0.351*** 0.295***  
Treatment initiation month 0.576*** 0.597*** 0.606*** 0.569***  
1 month after treatment 0.358*** 0.379*** 0.468*** 0.424***  
2 months after treatment 0.191*** 0.213*** 0.149* 0.134*  
3 months after treatment 0.0584 0.0806** 0.103** 0.0550  
4 months after treatment 0.0190 0.0438 0.0678 -0.000425  
5 months after treatment 0.1000* 0.124*** 0.0743* 0.0428  
6 months after treatment 0.0680 0.0906* 0.0664 0.0154  
7 months after treatment 0.0201 0.0428 0.0479 -0.00503  
8 months after treatment 0.0548 0.0758* 0.0617 0.0299  
9 months after treatment 0.0112 0.0328 0.0454 -0.00863  
10 months after treatment 0.0531 0.0777* 0.0677 0.0213  
11 months after treatment 0.0597 0.0866* 0.0702 0.0508  
12 months after treatment 0.0202 0.0469 0.0332 -0.00821  
            
Observations 20,929 20,929 13,539 18,567  
R-squared  0.017 0.021 0.020  
Number of id 1,001 1,001 500 799  
VARIABLES 
outpatient_visits Unbalanced 








          *** p<0.01, ** p<0.05, * p<0.1 
Fixed Effects N Y Y Y  
11 months before treatment -9.41e-06 -0.0103 0.0109 -0.0179  
10 months before treatment 0.0432 0.0233 0.0126 -0.0217  
9 months before treatment 0.0308 -0.000481 -0.0174 -0.0442  
8 months before treatment 0.0366 -0.00505 0.00149 -0.0685  
7 months before treatment 0.0695 0.0156 0.0450 -0.0178  
6 months before treatment 0.0645 -0.000470 0.0554 -0.0576  
5 months before treatment 0.117* 0.0420 0.151*** 0.0161  
4 months before treatment 0.259*** 0.171*** 0.277*** 0.127**  
3 months before treatment 0.251*** 0.151*** 0.262*** 0.123**  
2 months before treatment 0.419*** 0.303*** 0.364*** 0.244***  
1 month before treatment 0.953*** 0.828*** 0.875*** 0.786***  
Treatment initiation month 3.630*** 3.511*** 3.008*** 3.253***  
1 month after treatment 2.478*** 2.348*** 2.032*** 2.269***  
2 months after treatment 1.659*** 1.520*** 1.315*** 1.354***  
3 months after treatment 1.561*** 1.412*** 1.426*** 1.329***  
4 months after treatment 0.995*** 0.834*** 0.960*** 0.776***  
5 months after treatment 1.182*** 1.010*** 0.994*** 0.938***  
6 months after treatment 1.188*** 1.007*** 1.116*** 0.932***  
7 months after treatment 0.739*** 0.546*** 0.748*** 0.506***  
8 months after treatment 1.091*** 0.888*** 0.910*** 0.742***  
9 months after treatment 1.060*** 0.848*** 0.950*** 0.824***  
10 months after treatment 0.765*** 0.541*** 0.714*** 0.517***  
11 months after treatment 1.165*** 0.931*** 0.932*** 0.738***  
12 months after treatment 0.906*** 0.663*** 0.866*** 0.640***  
            
Observations 20,929 20,929 13,539 18,567  
R-squared  0.260 0.287 0.288  
Number of id 1,001 1,001 500 799  
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Summary Statistics 
 
Year Negative Positive 
Positive as a Percentage of 
Tested Unknown Total 
            
2009 7,395 1,248 1,248 667 9,310  
  79.43% 13.40% 14.43% 7.16% 100.00% 
2010 7,636 1,331 1,331 687 9,654  
  79.10% 13.79% 14.85% 7.12% 100.00% 
2011 7,596 1,350 1,350 478 9,424  
  80.60% 14.33% 15.10% 5.07% 100.00% 
2012 7,420 1,373 1,373 411 9,204  
  80.62% 14.92% 15.62% 4.47% 100.00% 
2013 7,521 1,400 1,400 291 9,212  
  81.64% 15.20% 15.70% 3.16% 100.00% 
2014 7,184 1,380 1,380 211 8,775  
  81.87% 15.73% 16.12% 2.40% 116.12% 
2015 6,958 1,337 1,337 141 8,436  
  82% 16% 16% 2% 100% 
2016 5,899 1,168 1,168 89 7,156  




year Untreated First Round Second Round Third Round Fourth Round Total Treated Total 
                
2009 343 1065 61 0 0 1126 1,469  
  23.35% 72.50% 4.15% 0.00% 0.00% 76.65% 100.00% 
2010 371 1057 79 8 0 1144 1,515  
  24.49% 69.77% 5.21% 0.53% 0.00% 75.51% 100.00% 
2011 355 1016 92 16 0 1124 1,479  
  24.00% 68.70% 6.22% 1.08% 0.00% 76.00% 100.00% 
2012 372 974 101 23 0 1098 1,470  
  25.31% 66.26% 6.87% 1.56% 0.00% 74.69% 100.00% 
2013 395 922 123 24 7 1076 1,471  
  26.85% 62.68% 8.36% 1.63% 0.48% 73.15% 100.00% 
2014 410 836 140 22 8 1006 1,416  
  28.95% 59.04% 9.89% 1.55% 0.56% 71.04% 100.00% 
2015 410 765 142 30 6 943 1,353  
  30% 57% 11% 2% 0% 69.70% 100% 
2016 380 645 113 28 4 790 1,170  
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